Intellia Therapeutics Inc buy Royal Bank of Canada
Start price
10.11.23
/
50%
€22.58
Target price
10.11.24
€65.49
Performance (%)
-28.32%
Price
20:29
€16.19
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -28.32%. This prediction currently runs until 10.11.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Intellia Therapeutics Inc | -13.172% | -13.172% |
iShares Core DAX® | -1.471% | 1.895% |
iShares Nasdaq 100 | -0.486% | 4.395% |
iShares Nikkei 225® | -2.115% | 2.450% |
iShares S&P 500 | 0.394% | 3.118% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Royal Bank of Canada from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€20.95
19.09.24
19.09.24
€48.55
19.09.25
19.09.25
-22.74%
20:29
20:29
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€19.65
09.08.24
09.08.24
€49.44
09.08.25
09.08.25
-17.61%
20:29
20:29